Epizyme, Inc. (NASDAQ:EPZM) – Equities researchers at Oppenheimer Holdings decreased their FY2020 earnings estimates for Epizyme in a report released on Tuesday. Oppenheimer Holdings analyst L. Cann now expects that the biopharmaceutical company will earn $1.60 per share for the year, down from their prior forecast of $1.84. Oppenheimer Holdings currently has a “Buy” rating and a $26.00 target price on the stock.
A number of other brokerages have also commented on EPZM. Leerink Swann reissued an “outperform” rating and set a $28.00 price objective (down previously from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. Royal Bank Of Canada reissued a “buy” rating and set a $20.00 price objective on shares of Epizyme in a report on Friday, September 15th. BidaskClub raised Epizyme from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Wednesday, July 12th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $23.33.
TRADEMARK VIOLATION NOTICE: This article was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.themarketsdaily.com/2017/09/20/fy2020-earnings-estimate-for-epizyme-inc-epzm-issued-by-oppenheimer-holdings.html.
Epizyme (EPZM) traded down 1.56% during trading on Wednesday, reaching $18.95. The company had a trading volume of 643,077 shares. Epizyme has a 12 month low of $8.38 and a 12 month high of $20.00. The stock has a 50 day moving average of $15.50 and a 200-day moving average of $15.25. The company’s market capitalization is $1.11 billion.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.95 million. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. Epizyme’s revenue for the quarter was up 2027.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.49) EPS.
Large investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its stake in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 795 shares during the period. UBS Asset Management Americas Inc. bought a new stake in Epizyme during the 1st quarter valued at approximately $175,000. BB&T Securities LLC bought a new stake in Epizyme during the 2nd quarter valued at approximately $181,000. Trexquant Investment LP bought a new stake in Epizyme during the 2nd quarter valued at approximately $184,000. Finally, SG Americas Securities LLC boosted its stake in Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 6,072 shares during the period. Hedge funds and other institutional investors own 83.74% of the company’s stock.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $14.87, for a total transaction of $223,050.00. Following the completion of the sale, the insider now owns 22,228 shares in the company, valued at approximately $330,530.36. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew E. Singer sold 3,024 shares of the stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $15.50, for a total value of $46,872.00. Following the sale, the chief financial officer now owns 40,529 shares of the company’s stock, valued at approximately $628,199.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,024 shares of company stock valued at $706,722. 25.20% of the stock is owned by corporate insiders.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.